Regenerative medicine company Locate Bio announced today that the FDA has granted breakthrough device designation to a bone graft/antibiotic combination designed to combat chronic bone infection, also known as osteomyelitis.
Osteomyelitis is a progressive, inflammatory infection of the bone, usually caused by bacteria and is estimated to account for up to 50% of all non-trauma related amputations. Currently, the standard treatment for chronic osteomyelitis is surgical debridement, long-term, high-dose administration of antibiotics, and — for larger defects — bone grafting, which often requires a second surgical procedure to remove the non-resorbable bone graft.
Get the full story on our sister site, Drug Delivery Business News.
"device" - Google News
January 08, 2021 at 04:00AM
https://ift.tt/2XyL8wZ
Locate Bio lands FDA breakthrough nod for bone infection device - Mass Device
"device" - Google News
https://ift.tt/2KSbrrl
https://ift.tt/2YsSbsy
Bagikan Berita Ini
0 Response to "Locate Bio lands FDA breakthrough nod for bone infection device - Mass Device"
Post a Comment